Stockreport

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody [Yahoo! Finance]

Oruka Therapeutics, Inc.  (ORKA) 
PDF On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026 Preclinical data [Read more]